Clinical Research Papers:
FGFR1 is an adverse outcome indicator for luminal A breast cancers
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1561 views | HTML 1893 views | ?
Yu-Jie Shi1, Julia Y.S. Tsang2, Yun-Bi Ni2, Siu-Ki Chan3, Kui-Fat Chan4, Gary M. Tse2
1Department of Pathology, Henan Province People's Hospital, Zhengzhou, Henan, China
2Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, NT, Hong Kong
3Department of Pathology, Kwong Wah Hospital, Kowloon, Hong Kong
4Department of Pathology, Tuen Mun Hosiptal, Tuen Mun, Hong Kong
Gary M. Tse, e-mail: [email protected]
Keywords: fibroblast growth factor receptor 1, breast cancer, luminal subtype, immunohistochemistry
Received: August 21, 2015 Accepted: November 21, 2015 Published: December 11, 2015
Fibroblast growth factor receptor 1 (FGFR1) has been suggested to be the candidate gene for 8p11–12 amplification in breast cancer and its therapeutic/ prognostic value is explored. Most previous studies focused on FGFR1 gene amplification, which may not necessarily lead to protein expression. Therefore, analysis of protein level may have more clinical relevance. We evaluated FGFR1 expression in a large cohort of breast cancer by immunohistochemistry, correlated with the tumor clinic-pathologic features, biomarkers expression, and patient’s survival. FGFR1 expression was associated mainly with luminal cancers, particularly luminal B subtype (23.5%; p < 0.001), and it also showed adverse prognostic impact on luminal A cancers. FGFR1 expression was associated with higher pN (p = 0.023), pT (p = 0.003) stages, lymphovascular invasion (p = 0.010), p-cadherin (p = 0.028), synaptophysin (p = 0.009) and SOX2 expression (p = 0.034) in luminal A cancers. FGFR1 expressing luminal A cancers showed a similar outcome as luminal B cancers. Multivariate Cox regression analysis demonstrated FGFR1 positive luminal A cancers to be an independently poor prognosticator for disease free survival in luminal cancers (hazard ratio = 3.341, p = 0.008). Thus FGFR1 could be useful in identifying the aggressive cases amongst heterogeneous luminal A cancers. Given the relevance of FGFR pathway in treatment resistance in luminal cancers, FGFR1 could be an important tumor biomarker and adverse prognostic factor potentially exploitable in the clinical management of luminal cancers.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.